Evaro, an NHS licensed digital healthcare platform that says it serves more than 2 million patients, has raised a $25 million Series A round led by AlbionVC, with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI. The company positions itself as a healthcare-as-a-service provider that enables consumer brands, healthcare organisations, and employers to offer regulated digital care without building their own clinical or pharmacy infrastructure.
The platform already partners with period tracking app Clue and sexual wellness retailer Lovehoney, embedding prescription services into those customer experiences. Evaro says the new capital will be used to scale this model across three core customer segments: consumer brands seeking incremental revenue and retention, healthcare organisations looking to expand digital capacity for common conditions, and employers deploying health benefits.
The raise comes against a backdrop of rising pressure on UK primary care access. The company cites data showing that 20.5 million people experienced month-long waits for a GP appointment in 2024, up 60% over seven years, framing its product as a way to divert appropriate lower-acuity care from in-person appointment pathways. Evaro’s offering includes asynchronous consultations, remote diagnostics, prescribing, dispensing, and aftercare, delivered through an API-first stack designed to be embedded in partner platforms. The company says partner integrations can be completed in as little as two weeks, allowing brands to launch healthcare journeys quickly while keeping implementation burden low.
Evaro was founded in 2018 by emergency physician Dr. Thuria Wenbar and pharmacist researcher Dr. Oskar Wenbar. The company says it holds CQC and GPhC licences dating back to 2018, maintains seven active regulatory approvals, and supports NHS integration, including GP record access to enable safer prescribing. It also cites a 4.5 Trustpilot rating as an indicator of patient satisfaction.
AlbionVC partner Christoph Ruedig is joining Evaro’s board as part of the financing. Evaro says it will use the funding to expand treatment areas, including women’s health, men’s health, and longevity medicine, strengthen clinical capabilities, such as diagnostics and aftercare, and continue platform development focused on seamless brand integration.
Looking ahead, Evaro says it aims to serve 10 million patients over the next three years and establish healthcare as a service as a distinct category in the UK. The company also notes that Dr. Thuria Wenbar and Dr. Oskar Wenbar were recently named to The Times’ LDC Top 50 Most Ambitious Business Leaders of 2025.
KEY QUOTES
“When a third of people are waiting over a week just to see their GP, it’s time to think through alternative solutions that help people get the care they need while supporting NHS capacity. What we’ve built is infrastructure that allows our partners – brands people already trust – to deliver safe and regulated healthcare for common conditions without having to build a thing. We’re making healthcare as accessible as online banking, and this funding lets us prove that model works at scale.”
Dr. Thuria Wenbar, CEO and co-founder of Evaro
“We’ve seen embedded finance transform banking, Evaro is now driving the embedded health revolution. Evaro has spent seven years building its infrastructure properly, with deep regulatory credentials. This now allows consumer brands to enter the healthcare space safely, unlocking massive latent demand while relieving pressure on the NHS. We are thrilled to back the team as they define this new category.”
Christoph Ruedig, Partner at AlbionVC
“Patients now expect the same convenience from healthcare that they get from banking or shopping—instant, mobile, on their terms. The technology exists to deliver this for minor conditions, but our system is still stuck requiring appointments, phone calls, physical visits – with no capacity for smart aftercare. We want to solve this, and scale the infrastructure that matches how people actually want to access care in 2026.”
Dr. Oskar Wenbar, Chief Medical Officer and co-founder of Evaro
